Clinical Trials

43 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT06149286 2026-03-06

OLYMPIA-5

Phase 3 Recruiting

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT03601078 2026-03-04

KarMMa-2

312 enrolled

Multiple Myeloma, Recurrence

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-02-20

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT04712097 2026-02-04

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Multiple Myeloma, Recurrence

NCT02390869 2025-12-02

FIL_RENOIR12

128 enrolled

Lymphoma, Follicular, Recurrence

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07126236 2025-08-17

REPIFIR

80 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Multiple Myeloma, Recurrence

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

22 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04036448 2025-03-11

RevlimidPMS

Completed

28 enrolled

LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT03647124 2025-03-04

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Completed

105 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT03836014 2024-12-06

CONFIRM

436 enrolled

Multiple Myeloma, Recurrence

NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

150 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01199575 2024-08-15

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

30 enrolled 12 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03859427 2024-08-13

ARROW2

Phase 3 Completed

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT00799513 2024-04-10

RV-NHL-PI351

48 enrolled 17 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

27 enrolled 13 charts

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

20 enrolled

Recurrence, Lymphoma, B-Cell

NCT04113226 2023-02-08

Relyage

Phase 2 Unknown

114 enrolled

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT03302728 2022-05-19

EpiBrentlen

6 enrolled

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

38 enrolled

Multiple Myeloma, Recurrence

NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Phase 1/2 Terminated

3 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00981708 2021-04-30

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

37 enrolled

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Recurrence

NCT01380106 2021-01-25

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Recurrence

NCT01956695 2020-12-17

REVRI

45 enrolled

Lymphoma, Recurrence

NCT00642954 2020-11-18

MK-0683-074

31 enrolled 13 charts

Multiple Myeloma, Recurrence

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 2 Unknown

44 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT01788189 2020-02-26

LeMLAR

37 enrolled

Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04109872 2020-02-05

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Unknown

25 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT02538965 2020-01-07

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Other hematologic neoplasm

17 enrolled 21 charts

Leukemia, Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00065351 2019-11-12

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

222 enrolled

Multiple Myeloma, Recurrence

NCT02348528 2019-11-12

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

65 enrolled

Multiple Myeloma, Recurrence

NCT00419250 2019-11-08

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

52 enrolled

Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01729104 2019-10-22

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02060656 2019-09-19

LEGEND

Phase 2 Unknown

92 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00963105 2018-10-31

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

104 enrolled 18 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02075021 2018-10-15

rev/abraxane

Phase 1/2 Terminated

3 enrolled 3 charts

Multiple Myeloma, Recurrence

NCT02986451 2018-08-14

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT02206503 2018-08-02

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

13 enrolled

Multiple Myeloma, Recurrence

NCT00538824 2018-06-06

DexTR

Phase 2 Terminated

5 enrolled 8 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02983097 2018-01-19

R²-DHAP

Phase 1/2 Terminated

34 enrolled